# Beginning of Effective and Safe Treatment in Immunoglobulin A-1 Nephropathy-1

> **NCT03357653** · PHASE3 · UNKNOWN · sponsor: **Ewha Womans University** · enrollment: 174 (estimated)

## Conditions studied

- Glomerulonephritis, Immunoglobulin A (IgA)

## Interventions

- **DRUG:** Losartan group
- **DRUG:** Placebo group

## Key facts

- **NCT ID:** NCT03357653
- **Lead sponsor:** Ewha Womans University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-01-30
- **Primary completion:** 2021-12-31
- **Final completion:** 2021-12-31
- **Target enrollment:** 174 (ESTIMATED)
- **Last updated:** 2017-11-30

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03357653

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03357653, "Beginning of Effective and Safe Treatment in Immunoglobulin A-1 Nephropathy-1". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03357653. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*